Auris Medical Announces Positive Top-Line Data from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain and Provides Update on TRAVERS Phase 2 Study Administration of intranasal betahistine 30 mg shows statistically significant reduction in olanzapine-induced weight gainTreatment well tolerated and safe with no adverse effectsEnrollment into Phase...

Auris Medical Announces Positive Interim Results from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain Hamilton, Bermuda, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...

Auris Medical Completes Enrollment of Phase 1b Proof-Of-Concept Trial of AM-201 in Antipsychotic-Induced Weight Gain Hamilton, Bermuda, July 03, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...

Auris Medical Reaches Midpoint for Enrollment in AM-201 Phase 1b Proof-of-Concept Study in Antipsychotic-Induced Weight Gain Hamilton, Bermuda, May 07, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...